Avlar was founded in 1999 by Alan Goodman and Daniel Roach and manages Avlar Fund II (Â£43m) and the First Cambridge Gateway Fund (Â£35m). Avlar has invested in eighteen companies across a range of sub-sectors of the bioscience industries. Ten are still private, two have been merged, three have been bought by public companies, two have been sold for cash and two listed on the public markets. Prior to the formation of Avlar Messrs Roach and Goodman co-founded or seed financed nine life science companies. Seven of these were listed on recognized Stock Exchanges producing highly profitable realizations. These included Acambis, Chiroscience, Core, Salix and Oxford Biomedica.
|Crescendo Biologics||1/10||Series A||$7.3M||3|
|Takeda Cambridge||7/06||Series D||$13M||3|
|Takeda Cambridge||1/05||Venture Round||$9.38M||3|